Morgan Stanley Nex Immune, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.2 - $0.3 $89 - $133	446 New	446 $0
Q4 2022 Feb 14, 2023	SELL	$0.21 - $18.5 $550 - $48,507	-2,622 Reduced 76.29%	815 $0
Q3 2022 Nov 14, 2022	SELL	$0.6 - $17.5 $7,992 - $233,100	-13,320 Reduced 79.49%	3,437 $2,000
Q2 2022 Oct 27, 2022	BUY	$1.61 - $4.68 $20,796 - $60,451	12,917 Added 336.38%	16,757 $27,000
Q2 2022 Aug 15, 2022	BUY	$1.61 - $4.68 $20,796 - $60,451	12,917 Added 336.38%	16,757 $27,000
Q1 2022 Oct 27, 2022	SELL	$1.79 - $4.65 $23,121 - $60,064	-12,917 Reduced 77.08%	3,840 $16,000
Q1 2022 May 13, 2022	SELL	$1.79 - $4.65 $60,602 - $157,430	-33,856 Reduced 89.81%	3,840 $16,000
Q4 2021 Feb 14, 2022	BUY	$4.11 - $15.13 $145,383 - $535,193	35,373 Added 1522.73%	37,696 $174,000
Q3 2021 Nov 15, 2021	BUY	$10.32 - $16.9 $23,973 - $39,258	2,323 New	2,323 $35,000

Ticker NEXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,155,600
Market Cap $7.25M
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's pr...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.